[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646893":3},{"organization":4,"outcomesModule":7,"designInfo":46,"detailedDescription":11,"studyPopulation":11,"armGroups":55,"interventions":96,"overallOfficials":108,"centralContacts":112,"locations":118,"responsibleParty":523,"collaborators":11,"id":525,"slug":526,"hasResults":527,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":11,"eligibilityCriteria":531,"healthyVolunteers":527,"sex":532,"minAge":533,"maxAge":534,"enrollmentInfo":535,"targetDuration":11,"studyType":538,"phases":539,"briefSummary":541,"conditions":542,"keywords":546,"overallStatus":121,"whyStopped":11,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":562},{"fullName":5,"class":6},"Amgen","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Percent Change in Body Weight from Baseline of the Parent Trial (20210184)",null,"Baseline of parent trial (20210184) to Week 48 of current trial",{"measure":14,"description":11,"timeFrame":15},"Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","Baseline of current trial up to 60 weeks",[17,20,22,24,26,28,30,32,35,38,40,42,44],{"measure":18,"description":11,"timeFrame":19},"Percentage of Participants Achieving ≥ 5% Reduction in Body Weight from Baseline of the Parent Trial","Baseline of parent trial to Week 48 of current trial",{"measure":21,"description":11,"timeFrame":19},"Percentage of Participants Achieving ≥ 10% Reduction in Body Weight from Baseline of the Parent Trial",{"measure":23,"description":11,"timeFrame":19},"Percentage of Participants Achieving ≥ 15% Reduction in Body Weight from Baseline of the Parent Trial",{"measure":25,"description":11,"timeFrame":19},"Percentage of Participants Achieving ≥ 20% Reduction in Body Weight from Baseline of the Parent Trial",{"measure":27,"description":11,"timeFrame":19},"Change from Baseline of the Parent Trial in Hemoglobin A1c",{"measure":29,"description":11,"timeFrame":19},"Change from Baseline of the Parent Trial in Waist Circumference",{"measure":31,"description":11,"timeFrame":19},"Change from Baseline of the Parent Trial in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score",{"measure":33,"description":11,"timeFrame":34},"Percent Change from Baseline in Body Weight","Baseline of current trial to Week 48",{"measure":36,"description":11,"timeFrame":37},"Percentage of Participants with No Body Weight Gain of >3% From Baseline","Week 48 of current trial",{"measure":39,"description":11,"timeFrame":37},"Percentage of Participants with No Body Weight Gain of >5% From Baseline",{"measure":41,"description":11,"timeFrame":19},"Percentage of Body Weight Reduction Maintained from the Parent Trial",{"measure":43,"description":11,"timeFrame":19},"Percentage of Participants Maintaining ≥ 80% of the Body Weight Reduction Achieved in the Parent Trial",{"measure":45,"description":11,"timeFrame":37},"Change from Baseline in HbA1c",{"allocation":47,"interventionModel":48,"interventionModelDescription":11,"primaryPurpose":49,"observationalModel":11,"timePerspective":11,"maskingInfo":50},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":51,"maskingDescription":11,"whoMasked":52},"DOUBLE",[53,54],"PARTICIPANT","INVESTIGATOR",[56,62,66,70,76,80,84,88,92],{"label":57,"type":58,"description":59,"interventionNames":60},"Maridebart Cafraglutide Low Dose Q4W","EXPERIMENTAL","Participants who received low dose of maridebart cafraglutide in the parent trial (20210184 \\[NCT06858878\\]) will continue to receive low dose of maridebart cafraglutide subcutaneously (SC) once in 4 weeks (Q4W).",[61],"Drug: Maridebart Cafraglutide",{"label":63,"type":58,"description":64,"interventionNames":65},"Maridebart Cafraglutide Medium Dose Q4W","Participants who received medium dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive medium dose of maridebart cafraglutide SC Q4W.",[61],{"label":67,"type":58,"description":68,"interventionNames":69},"Maridebart Cafraglutide Medium dose Q8W","Participants who received medium dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive medium dose of maridebart cafraglutide SC once in 8 weeks (Q8W).",[61],{"label":71,"type":72,"description":73,"interventionNames":74},"Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial)","PLACEBO_COMPARATOR","Participants who received medium dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive placebo SC Q4W.",[75],"Drug: Placebo",{"label":77,"type":58,"description":78,"interventionNames":79},"Maridebart Cafraglutide High Dose Q4W","Participants who received high dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive high dose of maridebart cafraglutide SC Q4W.",[61],{"label":81,"type":58,"description":82,"interventionNames":83},"Maridebart Cafraglutide High Dose Q8W","Participants who received high dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive high dose of maridebart cafraglutide SC Q8W.",[61],{"label":85,"type":72,"description":86,"interventionNames":87},"Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial)","Participants who received high dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive placebo SC Q4W.",[75],{"label":89,"type":58,"description":90,"interventionNames":91},"Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial)","Participants who received placebo in the parent trial will receive high dose of maridebart cafraglutide SC Q4W. Prior to initiating the assigned high dose, participants will undergo a dose-escalation phase gradually increasing doses.",[61],{"label":93,"type":58,"description":94,"interventionNames":95},"Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)","Participants who permanently de-escalated to very low dose of maridebart cafraglutide in the parent trial will receive low dose of maridebart cafraglutide SC Q4W.",[61],[97,105],{"type":98,"name":99,"description":100,"armGroupLabels":101,"otherNames":102},"DRUG","Maridebart Cafraglutide","Administered subcutaneously.",[77,89,81,57,93,63,67],[103,104],"AMG 133","MariTide",{"type":98,"name":106,"description":100,"armGroupLabels":107,"otherNames":11},"Placebo",[85,71],[109],{"name":110,"affiliation":5,"role":111},"MD","STUDY_DIRECTOR",[113],{"name":114,"role":115,"phone":116,"phoneExt":11,"email":117},"Amgen Call Center","CONTACT","866-572-6436","medinfo@amgen.com",[119,133,143,152,161,170,179,189,195,204,213,222,231,241,251,261,270,279,289,299,309,319,329,339,349,355,365,375,384,393,402,412,424,436,441,446,456,465,469,478,483,492,497,501,512],{"facility":120,"status":121,"city":122,"state":123,"zip":124,"country":125,"countryCode":126,"cosmosGeoPoint":127,"geoPoint":132,"contacts":11},"Gilbert Center for Family Medicine","RECRUITING","Gilbert","Arizona","85296","United States","US",{"type":128,"coordinates":129},"Point",[130,131],-111.78903,33.35283,{"lat":131,"lon":130},{"facility":134,"status":121,"city":135,"state":136,"zip":137,"country":125,"countryCode":126,"cosmosGeoPoint":138,"geoPoint":142,"contacts":11},"San Fernando Valley Health Institute","Canoga Park","California","91304",{"type":128,"coordinates":139},[140,141],-118.59814,34.20112,{"lat":141,"lon":140},{"facility":144,"status":121,"city":145,"state":136,"zip":146,"country":125,"countryCode":126,"cosmosGeoPoint":147,"geoPoint":151,"contacts":11},"Core Healthcare Group","Cerritos","90703",{"type":128,"coordinates":148},[149,150],-118.06479,33.85835,{"lat":150,"lon":149},{"facility":153,"status":121,"city":154,"state":136,"zip":155,"country":125,"countryCode":126,"cosmosGeoPoint":156,"geoPoint":160,"contacts":11},"Velocity Clinical Research Chula Vista","La Mesa","91942",{"type":128,"coordinates":157},[158,159],-117.02308,32.76783,{"lat":159,"lon":158},{"facility":162,"status":121,"city":163,"state":136,"zip":164,"country":125,"countryCode":126,"cosmosGeoPoint":165,"geoPoint":169,"contacts":11},"Paradigm Clinical Research","Modesto","95355",{"type":128,"coordinates":166},[167,168],-120.99688,37.6391,{"lat":168,"lon":167},{"facility":171,"status":121,"city":172,"state":136,"zip":173,"country":125,"countryCode":126,"cosmosGeoPoint":174,"geoPoint":178,"contacts":11},"Empire Clinical Research","Pomona","91767",{"type":128,"coordinates":175},[176,177],-117.75228,34.05529,{"lat":177,"lon":176},{"facility":180,"status":121,"city":181,"state":182,"zip":183,"country":125,"countryCode":126,"cosmosGeoPoint":184,"geoPoint":188,"contacts":11},"San Marcus Research Clinic Inc","Miami","Florida","33015",{"type":128,"coordinates":185},[186,187],-80.19366,25.77427,{"lat":187,"lon":186},{"facility":190,"status":121,"city":181,"state":182,"zip":191,"country":125,"countryCode":126,"cosmosGeoPoint":192,"geoPoint":194,"contacts":11},"Optimus U Corporation","33135",{"type":128,"coordinates":193},[186,187],{"lat":187,"lon":186},{"facility":196,"status":121,"city":197,"state":182,"zip":198,"country":125,"countryCode":126,"cosmosGeoPoint":199,"geoPoint":203,"contacts":11},"Indago Research and Health Center","Miami Lakes","33016",{"type":128,"coordinates":200},[201,202],-80.30866,25.90871,{"lat":202,"lon":201},{"facility":205,"status":121,"city":206,"state":182,"zip":207,"country":125,"countryCode":126,"cosmosGeoPoint":208,"geoPoint":212,"contacts":11},"Florida Institute for Clinical Research","Orlando","32825",{"type":128,"coordinates":209},[210,211],-81.37924,28.53834,{"lat":211,"lon":210},{"facility":214,"status":121,"city":215,"state":182,"zip":216,"country":125,"countryCode":126,"cosmosGeoPoint":217,"geoPoint":221,"contacts":11},"Encore Medical Research of Weston LLC","Weston","33331",{"type":128,"coordinates":218},[219,220],-80.39977,26.10037,{"lat":220,"lon":219},{"facility":223,"status":121,"city":224,"state":182,"zip":225,"country":125,"countryCode":126,"cosmosGeoPoint":226,"geoPoint":230,"contacts":11},"Conquest Research - Winter Park","Winter Park","32789",{"type":128,"coordinates":227},[228,229],-81.33924,28.6,{"lat":229,"lon":228},{"facility":232,"status":121,"city":233,"state":234,"zip":235,"country":125,"countryCode":126,"cosmosGeoPoint":236,"geoPoint":240,"contacts":11},"Endeavor Health","Skokie","Illinois","60077",{"type":128,"coordinates":237},[238,239],-87.73339,42.03336,{"lat":239,"lon":238},{"facility":242,"status":121,"city":243,"state":244,"zip":245,"country":125,"countryCode":126,"cosmosGeoPoint":246,"geoPoint":250,"contacts":11},"Iowa Diabetes Research","West Des Moines","Iowa","50266",{"type":128,"coordinates":247},[248,249],-93.71133,41.57721,{"lat":249,"lon":248},{"facility":252,"status":121,"city":253,"state":254,"zip":255,"country":125,"countryCode":126,"cosmosGeoPoint":256,"geoPoint":260,"contacts":11},"JCCT- Juno Northwest Houston","Lenexa","Kansas","66219",{"type":128,"coordinates":257},[258,259],-94.73357,38.95362,{"lat":259,"lon":258},{"facility":262,"status":121,"city":263,"state":254,"zip":264,"country":125,"countryCode":126,"cosmosGeoPoint":265,"geoPoint":269,"contacts":11},"Alliance for Multispecialty Research Newton","Newton","67114",{"type":128,"coordinates":266},[267,268],-97.34504,38.04668,{"lat":268,"lon":267},{"facility":271,"status":121,"city":272,"state":254,"zip":273,"country":125,"countryCode":126,"cosmosGeoPoint":274,"geoPoint":278,"contacts":11},"Alliance for Multispecialty Research LLC","Wichita","67226",{"type":128,"coordinates":275},[276,277],-97.33754,37.69224,{"lat":277,"lon":276},{"facility":280,"status":121,"city":281,"state":282,"zip":283,"country":125,"countryCode":126,"cosmosGeoPoint":284,"geoPoint":288,"contacts":11},"Ima Clinical Research- Monroe","Monroe","Louisiana","71201",{"type":128,"coordinates":285},[286,287],-92.1193,32.50931,{"lat":287,"lon":286},{"facility":290,"status":121,"city":291,"state":292,"zip":293,"country":125,"countryCode":126,"cosmosGeoPoint":294,"geoPoint":298,"contacts":11},"Annapolis Internal Medicine, LLC","Annapolis","Maryland","21401",{"type":128,"coordinates":295},[296,297],-76.49184,38.97859,{"lat":297,"lon":296},{"facility":300,"status":121,"city":301,"state":302,"zip":303,"country":125,"countryCode":126,"cosmosGeoPoint":304,"geoPoint":308,"contacts":11},"Alliance for Multispecialty Research - Kansas City","Kansas City","Missouri","64114",{"type":128,"coordinates":305},[306,307],-94.57857,39.09973,{"lat":307,"lon":306},{"facility":310,"status":121,"city":311,"state":312,"zip":313,"country":125,"countryCode":126,"cosmosGeoPoint":314,"geoPoint":318,"contacts":11},"Palm Research Center Inc","Las Vegas","Nevada","89148",{"type":128,"coordinates":315},[316,317],-115.13722,36.17497,{"lat":317,"lon":316},{"facility":320,"status":121,"city":321,"state":322,"zip":323,"country":125,"countryCode":126,"cosmosGeoPoint":324,"geoPoint":328,"contacts":11},"Premier Research","Trenton","New Jersey","08611",{"type":128,"coordinates":325},[326,327],-74.74294,40.21705,{"lat":327,"lon":326},{"facility":330,"status":121,"city":331,"state":332,"zip":333,"country":125,"countryCode":126,"cosmosGeoPoint":334,"geoPoint":338,"contacts":11},"West Clinical Research","Morehead City","North Carolina","28557",{"type":128,"coordinates":335},[336,337],-76.72604,34.72294,{"lat":337,"lon":336},{"facility":340,"status":121,"city":341,"state":342,"zip":343,"country":125,"countryCode":126,"cosmosGeoPoint":344,"geoPoint":348,"contacts":11},"Velocity Clinical Research - Cincinnati","Cincinnati","Ohio","45242",{"type":128,"coordinates":345},[346,347],-84.51439,39.12711,{"lat":347,"lon":346},{"facility":350,"status":121,"city":341,"state":342,"zip":351,"country":125,"countryCode":126,"cosmosGeoPoint":352,"geoPoint":354,"contacts":11},"Velocity Clinical Research - Springdale","45246",{"type":128,"coordinates":353},[346,347],{"lat":347,"lon":346},{"facility":356,"status":121,"city":357,"state":358,"zip":359,"country":125,"countryCode":126,"cosmosGeoPoint":360,"geoPoint":364,"contacts":11},"Velocity Clinical Research - Providence","East Greenwich","Rhode Island","02818",{"type":128,"coordinates":361},[362,363],-71.45589,41.66038,{"lat":363,"lon":362},{"facility":366,"status":121,"city":367,"state":368,"zip":369,"country":125,"countryCode":126,"cosmosGeoPoint":370,"geoPoint":374,"contacts":11},"Elligo Clinical Research Center","Austin","Texas","78704",{"type":128,"coordinates":371},[372,373],-97.74306,30.26715,{"lat":373,"lon":372},{"facility":376,"status":121,"city":377,"state":368,"zip":378,"country":125,"countryCode":126,"cosmosGeoPoint":379,"geoPoint":383,"contacts":11},"Johnson County Clinical Trials Juno Bellaire","Bellaire","77401",{"type":128,"coordinates":380},[381,382],-95.45883,29.70579,{"lat":382,"lon":381},{"facility":385,"status":121,"city":386,"state":368,"zip":387,"country":125,"countryCode":126,"cosmosGeoPoint":388,"geoPoint":392,"contacts":11},"Osvaldo A Brusco MD PA","Corpus Christi","78414",{"type":128,"coordinates":389},[390,391],-97.39638,27.80058,{"lat":391,"lon":390},{"facility":394,"status":121,"city":395,"state":368,"zip":396,"country":125,"countryCode":126,"cosmosGeoPoint":397,"geoPoint":401,"contacts":11},"Soma Clinical Trials, LLC","Denison","75020",{"type":128,"coordinates":398},[399,400],-96.53666,33.75566,{"lat":400,"lon":399},{"facility":403,"status":121,"city":404,"state":405,"zip":406,"country":125,"countryCode":126,"cosmosGeoPoint":407,"geoPoint":411,"contacts":11},"Manassas Clinical Research Center Inc","Burke","Virginia","22015",{"type":128,"coordinates":408},[409,410],-77.27165,38.79345,{"lat":410,"lon":409},{"facility":413,"status":121,"city":414,"state":415,"zip":416,"country":417,"countryCode":418,"cosmosGeoPoint":419,"geoPoint":423,"contacts":11},"Hamilton Medical Research Group","Hamilton","Ontario","L8L 5G4","Canada","CA",{"type":128,"coordinates":420},[421,422],-79.84963,43.25011,{"lat":422,"lon":421},{"facility":425,"status":121,"city":426,"state":427,"zip":428,"country":429,"countryCode":430,"cosmosGeoPoint":431,"geoPoint":435,"contacts":11},"Mikannohana Clinic, Diabetes, Endocrinology and Metabolism","Matsuyama","Ehime","790-0034","Japan","JP",{"type":128,"coordinates":432},[433,434],132.76574,33.83916,{"lat":434,"lon":433},{"facility":437,"status":121,"city":438,"state":439,"zip":440,"country":429,"countryCode":430,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Morizono Medical Clinic","Kitakyusyu-shi","Fukuoka","807-0072",{"facility":442,"status":121,"city":443,"state":444,"zip":445,"country":429,"countryCode":430,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Mazda Hospital of Mazda Motor Corporation","Aki-gun","Hiroshima","735-8585",{"facility":447,"status":121,"city":448,"state":449,"zip":450,"country":429,"countryCode":430,"cosmosGeoPoint":451,"geoPoint":455,"contacts":11},"Nakamoto Medical Clinic","Mito","Ibaraki","310-0826",{"type":128,"coordinates":452},[453,454],140.45,36.35,{"lat":454,"lon":453},{"facility":457,"status":121,"city":458,"state":449,"zip":459,"country":429,"countryCode":430,"cosmosGeoPoint":460,"geoPoint":464,"contacts":11},"Nakakinen Clinic","Naka","311-0113",{"type":128,"coordinates":461},[462,463],140.16667,36.05,{"lat":463,"lon":462},{"facility":466,"status":121,"city":467,"state":449,"zip":468,"country":429,"countryCode":430,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Ohishi Naika Clinic","Tsuchiura-shi","300-0835",{"facility":470,"status":121,"city":471,"state":471,"zip":472,"country":429,"countryCode":430,"cosmosGeoPoint":473,"geoPoint":477,"contacts":11},"Morinaga Ueno Clinic","Kumamoto","860-0863",{"type":128,"coordinates":474},[475,476],130.69181,32.80589,{"lat":476,"lon":475},{"facility":479,"status":121,"city":480,"state":481,"zip":482,"country":429,"countryCode":430,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Shiraiwa Medical Clinic","Kashiwara-shi","Osaka","582-0005",{"facility":484,"status":121,"city":485,"state":485,"zip":486,"country":429,"countryCode":430,"cosmosGeoPoint":487,"geoPoint":491,"contacts":11},"Suruga Clinic","Shizuoka","424-0855",{"type":128,"coordinates":488},[489,490],138.38333,34.98333,{"lat":490,"lon":489},{"facility":493,"status":121,"city":494,"state":495,"zip":496,"country":429,"countryCode":430,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Yutenji Medical Clinic","Meguro-ku","Tokyo","153-0053",{"facility":498,"status":121,"city":499,"state":495,"zip":500,"country":429,"countryCode":430,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Medical Corporation Ouitsukai Kanno Naika","Mitaka-shi","181-0013",{"facility":502,"status":121,"city":503,"state":11,"zip":504,"country":505,"countryCode":506,"cosmosGeoPoint":507,"geoPoint":511,"contacts":11},"Latin Clinical Trial Center","San Juan","00909","Puerto Rico","PR",{"type":128,"coordinates":508},[509,510],-66.10572,18.46633,{"lat":510,"lon":509},{"facility":513,"status":121,"city":514,"state":11,"zip":515,"country":516,"countryCode":517,"cosmosGeoPoint":518,"geoPoint":522,"contacts":11},"FutureMeds Birmingham","Birmingham","B21 9RY","United Kingdom","UK",{"type":128,"coordinates":519},[520,521],-1.89983,52.48142,{"lat":521,"lon":520},{"type":524,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100646893","phase-3-extension-trial-to-evaluate-the-long-term-efficacy-safety-and-tolerability-of-maridebart-cafraglutide-maritime-2-extension-100646893",false,"NCT07684144","Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)","A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Signed informed consent form (ICF) indicating compliance with the requirements and restrictions listed in the ICF and this protocol.\n* Participants completing Study 20210184 must meet the following criteria:\n\n  * Completed the Week 72 visit in Study 20210184.\n  * Did not permanently discontinue the investigational product in the parent trial (20210184).\n  * Randomized within 7 days of week 72 visit in the parent trial.\n* Participants must use protocol-specified contraception during treatment and for 16 weeks after the last dose of trial intervention.\n\nExclusion Criteria:\n\n* Planned (during the trial) surgical, endoscopic, or device-based treatment for obesity.\n* Body mass index (BMI) ≤ 18.5 kilograms per meter square (kg\u002Fm\\^2).\n* Participant has known sensitivity to any of the products or components to be administered during dosing.\n* History of ischemic optic neuropathy.\n* Any malignancy diagnosed during the parent trial, except for the following treated with curative intent:\n\n  * Nonmelanoma skin cancers\n  * Breast ductal carcinoma in situ\n  * Cervical carcinoma in situ\n  * Prostate cancer in situ\n* Newly identified (during the parent trial) multiple endocrine neoplasia syndrome type 2, or family history (first-degree relative\\[s\\]) history of medullary thyroid carcinoma (MTC).\n* Patient Health Questionnaire-9 (PHQ-9) score ≥ 15 at the Week 72 visit from the parent trial (20210184) before randomization.\n* Any suicidal ideation (category 4 or 5) or any suicidal behavior on the Columbia-Suicide Severity Rating Scale (C-SSRS), Since Last Visit version, at the Week 72 visit from the parent trial before randomization.\n* Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements, in the judgment of the individual and investigator.\n* History or evidence of any other clinically significant disorder, condition, disease (including, but not limited to known drug or alcohol abuse, eating disorders, and conditions identified during the parent trial) that, in the opinion of the investigator, would pose a risk to participant safety.\n* Currently pregnant (confirmed with positive pregnancy test) or breastfeeding or planning to become pregnant or breastfeed while on trial until an additional 16 weeks after the last dose of trial intervention.\n* Major surgical procedures planned during the trial.\n* Participants with minor surgical procedures (not requiring general anesthesia or deep sedation) planned during the trial may be eligible at the discretion of the investigator.\n* Investigative site personnel directly affiliated with the trial and\u002For their immediate family (ie, spouse, parent, child, or sibling, whether biological or legally adopted).","ALL","18 Years","99 Years",{"count":536,"type":537},950,"ESTIMATED","INTERVENTIONAL",[540],"PHASE3","The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).",[543,544,545],"Obesity","Overweight","Diabetes Mellitus, Type 2",[547,548,549,543,544,99,104,550,551,552],"Type 2 Diabetes Mellitus","T2DM","BMI","Chronic Weight Management","Extension","Long-Term","2026-10-01",{"date":555,"type":556},"2026-10-05","ACTUAL",{"date":558,"type":556},"2026-07-29",{"date":560,"type":537},"2028-03-19",{"name":5,"class":6},45]